Abstract:The use of antagonists for each adenosine receptor (AR) subtype as potent clinical candidates is of growing interest due to their involvement in the treatment of various diseases. The recent resolution of several A(1) and A(2A) ARs X-ray structures provides opportunities for structure-based drug design. In this study, we describe the discovery of novel A(1)AR antagonists by applying a multistage virtual screening approach, which is based on random forest (RF), e-pharmacophore modeling and docking methods. A multistage virtual screening approach was applied to screen the ChemDiv library (1,492,362 compounds). Among the final hits, 22 compounds were selected for further radioligand binding assay analysis against human A(1)AR, and 18 compounds (81.82% success) exhibited nanomolar or low micromolar binding potency (K-i). Then, we selected six compounds (pK(i) > 6) to further evaluate their antagonist profile in a cAMP functional assay, and we found that they had low micromolar antagonistic activity (pIC(50) = 5.51-6.38) for the A(1)AR. Particularly, four of six compounds (pK(i) > 6) showed very good affinity (pKi = 6.11-7.13) and selectively (>100-fold) for A(1)AR over A(2A)AR. Moreover, the novelty analysis suggested that four of six compounds (pK(i) > 6) were dissimilar to existing A(1)AR antagonists and hence represented novel A(1)AR antagonists. Further molecular docking and molecular dynamics (MD) studies showed that the three selective compounds 15, 20 and 22 were stabilized (RMSlig value <= 2 angstrom) inside the binding pocket of AAR with similar orientations to the docking pose in 100-ns MD simulations, whereas they escaped from the binding area of A(2A)AR with larger values of RMSlig (RMSlig >= 2 angstrom). We hope that these findings provide new insights into the discovery of drugs targeting A(1)AR and facilitate research on new drugs and treatments for A(1)AR-related human pathologies. (C) 2019 Elsevier Masson SAS. All rights reserved.

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Comparison of the Selectivity of Human Adenosine Receptor Antagonists Based on Structure and Pharmacophore Features

Exploring the Structural Determinants of Novel Xanthine Derivatives As A2B Adenosine Receptor Antagonists: a Computational Study

Comparative Pharmacophore Modeling of Human Adenosine Receptor A1 and A3 Antagonists

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Pharmacophore Modeling of Human Adenosine Receptor A2A Antagonists

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Receptor-based Molecular Modeling Study on Antagonist-Bound Human α1A, α1B and α1D-Adrenoceptors

Discovery of Highly Potent Adenosine A1 Receptor Agonists: Targeting Positron Emission Tomography Probes.

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Insights into binding modes of adenosine A2B antagonists with ligand-based and receptor-based methods

Computational Studies of the Binding Site of Α 1A -Adrenoceptor Antagonists

Insight into the binding mode and the structural features of the pyrimidine derivatives as human A2A adenosine receptor antagonists.

Progress in the pursuit of therapeutic adenosine receptor antagonists

Molecular Modeling Studies of Human A3 Adenosine Antagonists: Structural Homology and Receptor Docking

Affinity Mass Spectrometry-Based Fragment Screening Identified a New Negative Allosteric Modulator of the Adenosine A 2A Receptor Targeting the Sodium Ion Pocket

Discovery of Novel Antagonists on Β2-Adrenoceptor from Natural Products Using a Label-Free Cell Phenotypic Assay.

High throughput screening and structure-activity relationship study of potential α2A-adrenoceptor agonists by LANCETM cAMP assay.